During a live event, Mary Jo Fidler, MD, and participants discussed how an intermediate-risk regimen, insurance resistance, and limited experience with trilaciclib shape neutropenia prevention in extensive-stage disease.
|Videos|November 17, 2016
- NSCLC (Issue 11)
- Volume 4
- Issue 2
Clinical Trials Exploring Bevacizumab in NSCLC
Author(s)Catherine Shu, MD
Catherine Shu, MD, medical oncologist, Division of Hematology/Oncology, Columbia University Medical Center, discusses two clinical trials exploring the use of bevacizumab (Avastin) in patients with non-small cell lung cancer.
Advertisement
Articles in this issue
almost 10 years ago
Erlotinib Plus Bevacizumab in EGFR-Mutant NSCLCalmost 10 years ago
Expert Explores Treatments for Biomarker-Negative Lung Canceralmost 10 years ago
Erlotinib/Bevacizumab Combo Warrants Consideration for EGFR+ NSCLCalmost 10 years ago
The Significance of Surgery Quality in NSCLCalmost 10 years ago
Practice-Changing Translational Advances Predicted for NSCLCalmost 10 years ago
Addressing the Challenges of Treating Non-Driver NSCLCAdvertisement
Related to this article
For Hispanic Heritage Month, Narjust Florez, MD, discusses lung cancer risk, biomarker testing, and trial access in Hispanic and Latinx patients.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
Theodore Wagener, PhD, of The Ohio State University discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.
FDA grants 2 breakthrough therapy designations to Temab-A, speeding development for hard-to-treat colorectal cancer and c-Met–expressing lung cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
2
Durability of PFS and OS Benefit vs. Historical Control
3
Amivantamab vs. Emerging EGFR Bispecifics in HNSCC
4
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
5